Design of Group IIA Secreted/Synovial Phospholipase A 2 Inhibitors: An Oxadiazolone Derivative Suppresses Chondrocyte Prostaglandin E 2 Secretion
Jean-Edouard Ombetta, Natacha Thelier, Chang Zhi Dong et al. · 2010
Read Design of Group IIA Secreted/Synovial Phospholipase A 2 Inhibitors: An Oxadiazolone Derivative Suppresses Chondrocyte Prostaglandin E 2 Secretion by Jean-Edouard Ombetta, Natacha Thelier, Chang Zhi Dong et al. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0010914.txt.
Description
Jean-Edouard Ombetta, Natacha Thelier, Chang Zhi Dong and co-authors published this drug design study in PLOS ONE in 2010. An enzyme called group IIA phospholipase A2 helps produce prostaglandin E2, a major driver of pain and swelling in rheumatic joint disease. Blocking that enzyme is a long-standing goal, and the team used computer modeling to improve a known blocker.
They designed seven new variants of a starting compound, simulated how each would grip the enzyme, and then synthesized and tested them. The modeling rankings held up in lab assays, and one variant, C8, proved the strongest blocker of the set. It also suppressed prostaglandin release from joint cartilage cells. Ombetta and colleagues show a full design loop, from screen to cell, for a possible new class of anti-inflammatory drugs.
Catalog record
| CREATOR | Jean-Edouard Ombetta, Natacha Thelier, Chang Zhi Dong et al. |
|---|---|
| YEAR | 2010 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0010914